Literature DB >> 24028144

Changes of adiponectin and its receptors in rats following chronic renal failure.

Yan Yu1, Bai-jun Bao, Ya-ping Fan, Lan Shi, Shao-qing Li.   

Abstract

OBJECTIVE: To investigate changes of adiponectin and its receptors (Adipo R) in rats following chronic renal failure.
METHODS: Male SD rats were randomly divided into two groups: control group and chronic renal failure (CRF) group. The CRF group were gavaged with adenine (300 mg/kg/d) for 4 weeks and the control group with drinking water. All rats were anesthetized at 2nd or 4th week and blood and urine samples were collected for detection of renal function, 24 h urine protein and adiponectin concentration. Renal tissues were also collected for HE staining, immunohistochemistry and RT-PCR screening.
RESULTS: Compared with control group, the serum concentrations of urea and creatinine, 24 h urine protein excretion in the CRF group were significantly higher at 2nd week and further increased at 4th week (p < 0.05). The adiponectin levels in serum and urine in the CRF group were significantly higher than those of control group (p < 0.01). The renal expressions of Adipo R1 and Adipo R2 in CRF group were also significantly increased compared to control group (p < 0.01). The increased expressions of Adipo R1 and Adipo R2 were positively related to the adiponectin levels in serum, urine, and 24 h urine protein.
CONCLUSION: The significant changes in expression of adiponectin and its receptors in rat CRF model could be an adaptive response that may provide the basis to understand pathological changes in chronic kidney disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24028144     DOI: 10.3109/0886022X.2013.830975

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  8 in total

1.  Adiponectin receptor and adiponectin signaling in human tissue among patients with end-stage renal disease.

Authors:  Maria P Martinez Cantarin; Scott W Keith; Scott A Waldman; Bonita Falkner
Journal:  Nephrol Dial Transplant       Date:  2014-07-21       Impact factor: 5.992

2.  The Adiponectin Receptor Agonist AdipoRon Ameliorates Diabetic Nephropathy in a Model of Type 2 Diabetes.

Authors:  Yaeni Kim; Ji Hee Lim; Min Young Kim; Eun Nim Kim; Hye Eun Yoon; Seok Joon Shin; Bum Soon Choi; Yong-Soo Kim; Yoon Sik Chang; Cheol Whee Park
Journal:  J Am Soc Nephrol       Date:  2018-01-12       Impact factor: 10.121

3.  Association of serum adiponectin level with albuminuria in chronic kidney disease patients.

Authors:  Ha Yeon Kim; Eun Hui Bae; Seong Kwon Ma; Dong Wan Chae; Kyu Hun Choi; Yong-Soo Kim; Young-Hwan Hwang; Curie Ahn; Soo Wan Kim
Journal:  Clin Exp Nephrol       Date:  2015-10-07       Impact factor: 2.801

4.  Hypoadiponectinemia and the presence of metabolic syndrome in patients with chronic kidney disease: results from the KNOW-CKD study.

Authors:  Chang-Yun Yoon; Yung Ly Kim; Seung Hyeok Han; Tae-Hyun Yoo; Su-Ah Sung; Woo-Kyung Chung; Dong-Wan Chae; Yong-Soo Kim; Curie Ahn; Kyu Hun Choi
Journal:  Diabetol Metab Syndr       Date:  2016-11-14       Impact factor: 3.320

5.  Uric acid upregulates the adiponectin‑adiponectin receptor 1 pathway in renal proximal tubule epithelial cells.

Authors:  Qingmei Yang; Chensheng Fu; Jing Xiao; Zhibin Ye
Journal:  Mol Med Rep       Date:  2017-12-19       Impact factor: 2.952

Review 6.  Adiponectin in Chronic Kidney Disease.

Authors:  Jarosław Przybyciński; Violetta Dziedziejko; Kamila Puchałowicz; Leszek Domański; Andrzej Pawlik
Journal:  Int J Mol Sci       Date:  2020-12-09       Impact factor: 5.923

7.  Resveratrol increases AdipoR1 and AdipoR2 expression in type 2 diabetic nephropathy.

Authors:  Hoon Suk Park; Ji Hee Lim; Min Young Kim; Yaeni Kim; You Ah Hong; Sun Ryoung Choi; Sungjin Chung; Hyung Wook Kim; Bum Soon Choi; Yong Soo Kim; Yoon Sik Chang; Cheol Whee Park
Journal:  J Transl Med       Date:  2016-06-11       Impact factor: 5.531

8.  Adiponectin and its receptors are involved in hypertensive vascular injury.

Authors:  Ruimin Guo; Min Han; Juan Song; Jun Liu; Yanni Sun
Journal:  Mol Med Rep       Date:  2017-10-25       Impact factor: 2.952

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.